Emerging HIV drug resistance in the Resource-Poor World: Challenges and strategies

Journal of AIDS and Clinical Research

Volumn 4, Issue SPL ISSUE5, 2013, Pages

  Paydary, Koosha ^a,b   Esmaeeli, Shooka ^a,b   SeyedAlinaghi, SeyedAhmad ^a   Rouzrokh, Pouria ^b   Emamzadeh Fard, Sahra ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879723401     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.S5-006     Document Type: Article

References (55)

1. WHO (2012) HIV Drug resistance report.
2. Roberts JD, Bebenek K, Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. Science 242: 1171-1173.
3. Preston BD, Poiesz BJ, Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242: 1168-1171.
4. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350: 1023-1035.
5. Van Vaerenbergh K (2001) Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Verh K Acad Geneeskd Belg 63: 447-473.
6. Richman DD (2001) HIV chemotherapy. Nature 410: 995-1001.
7. Piacenti FJ (2006) An update and review of antiretroviral therapy. Pharmacotherapy 26: 1111-1133.
8. van Marle G, Church DL, Nunweiler KD, Cannon K, Wainberg MA, et al. (2010) Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. Retrovirology 7: 74.
9. Haase AT (1999) Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 17: 625-656.
10. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
11. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
12. Roberts JD, Bebenek K, Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. Science 242: 1171-1173.
13. Preston BD, Poiesz BJ, Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242: 1168-1171.
14. Banke S, Lillemark MR, Gerstoft J, Obel N, Jørgensen LB (2009) Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J Virol 83: 8916-8924.
15. García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W (2004) Transmitted Human Immunodeficiency Virus Type 1 Carrying the D67N or K219Q/E Mutation Evolves Rapidly to Zidovudine Resistance in vitro and Shows a High Replicative Fitness in the Presence of Zidovudine. J Virol 78: 7545-7552.
16. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, et al. (1996) Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 70: 1086-1090.
17. Bull JJ, Sanjuán R, Wilke CO (2007) Theory of lethal mutagenesis for viruses. J Virol 81: 2930-2939.
18. Miller V, de Béthune MP, Kober A, Stürmer M, Hertogs K, et al. (1998) Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 42: 3123-3129.
19. Kapoor A, Shapiro B, Shafer RW, Shulman N, Rhee SY, et al. (2008) Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients. Retrovirology 5: 7.
20. Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489.
21. Palumbi SR (2001) Humans as the world's greatest evolutionary force. Science 293: 1786-1790.
22. UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study; UK Register of HIV Seroconverters (2007) Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 21: 1035-1039.
23. Wang D, Hicks CB, Goswami ND, Tafoya E, Ribeiro RM, et al. (2011) Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. J Virol 85: 6403-6415.
24. Booth CL, Geretti AM (2007) Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056.
25. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, et al. (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18: 1393-1401.
26. Shafer RW (2002) Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 15: 247-277.
27. Mousavi SM, Hamkar R, Gouya MM, Safaie A, Zahraei SM, et al. (2010) Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study. Arch Virol 155: 329-334.
28. Buendia P, Cadwallader B, DeGruttola V (2009) A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance. Bioinformatics 25: 2522-2529.
29. SPREAD programme (2008) Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22: 625-635.
30. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, et al. (2004) The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189: 2174-2180.
31. WHO (2012) The first WHO report on HIV drug resistance.
32. Truong HM, Kellogg TA, McFarland W, Louie B, Klausner JD, et al. (2011) Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One 6: e25281.
33. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, et al. (2010) Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 24: 1203-1212.
34. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, et al. (1998) Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 339: 307-311.
35. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, et al. (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288: 181-188.
36. Yebra G, de Mulder M, Pérez-Elías MJ, Pérez-Molina JA, Galán JC, et al. (2011) Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS One 6: e26757.
37. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385-394.
38. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, et al. (2005) Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 40: 505-511.
39. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance (2001) Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 322: 1087-1088.
40. Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, et al. (2008) Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 48: 324-333.
41. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, et al. (2009) Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200: 1503-1508.
42. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, et al. (2010) Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 5: e12718.
43. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, et al. (1999) Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354: 729-733.
44. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, et al. (1999) HIV-1 drug resistance in newly infected individuals. JAMA 282: 1135-1141.
45. Sohn AH, Srikantiah P, Sungkanuparph S, Zhang F (2013) Transmitted HIV drug resistance in Asia. Curr Opin HIV AIDS 8: 27-33.
46. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK (2002) Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. MMWR Recomm Rep 137: 381-433.
47. Cvetkovic RS, Goa KL (2003) Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63: 769-802.
48. Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, et al (2009) Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. Infection 37: 438-444.
49. Ji H, Massé N, Tyler S, Liang B, Li Y, et al. (2010) HIV drug resistance surveillance using pooled pyrosequencing. PLoS One 5: e9263.
50. Treviño A, de Mendoza C, Caballero E, Rodríguez C, Parra P, et al. (2011) Drug resistance muta. tions in patients infected with HIV-2 living in Spain. J Antimicrob Chemother 66: 1484-1488.
51. Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, et al. (2012) Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. Antivir Ther 17: 577-583.
52. Tang MW, Shafer RW (2012) HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 72: e1-25.
53. Bercoff DP, Triqueneaux P, Lambert C, Oumar AA, Ternes AM, et al. (2010) Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology 7: 98.
54. Temereanca A, Ene L, Duiculescu D, Ruta S (2011) Major HIV resistance mutations in untreated Romanian patients. J Med Life 4: 151-157.
55. Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM (2011) Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 66: 1467-1480.